SCHEMBL2149147

SCHEMBL2149147

CCCCCC1CCN(CCCn2c(=O)[nH]c3ccccc32)CC1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 4/20 0.62
LMNA P02545 3/20 0.62
CHRM1 P11229 2/20 0.61
CYP2D6 P10635 3/20 0.60
CYP2C9 P11712 2/20 0.60
HTR7 P34969 5/20 0.58
HPGD P15428 1/20 0.57
PMP22 Q01453 3/20 0.56
MEN1 O00255 2/20 0.56
NR1I2 O75469 2/20 0.56
CYP1A2 P05177 2/20 0.56
CYP3A4 P08684 2/20 0.56
ADORA3 P0DMS8 2/20 0.56
DRD2 P14416 2/20 0.56
ADRA2C P18825 2/20 0.56
SLC6A2 P23975 2/20 0.56
HTR2A P28223 2/20 0.56
HTR2C P28335 2/20 0.56
SLC6A4 P31645 2/20 0.56
ADRA1A P35348 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2149426 0.97 P2RX7 (0.64) P2RX7LMNACHRM1CYP2D6CYP2C9
SCHEMBL2149702 0.94 CHRM1 (0.62) P2RX7LMNACHRM1CYP2D6CYP2C9
SCHEMBL2149595 0.91 CYP2D6 (0.60) P2RX7LMNACHRM1CYP2D6CYP2C9
SCHEMBL2149940 0.86 P2RX7 (0.68) P2RX7LMNACHRM1CYP2D6CYP2C9
SCHEMBL2150070 0.86 P2RX7 (0.59) P2RX7LMNACHRM1CYP2D6CYP2C9
SCHEMBL2150225 0.84 LMNA (0.67) P2RX7LMNACHRM1CYP2D6CYP2C9
SCHEMBL3036994 0.83 LMNA (0.70) P2RX7LMNACHRM1CYP2D6CYP2C9
SCHEMBL2154069 0.82 LMNA (0.72) P2RX7LMNACHRM1CYP2D6CYP2C9
SCHEMBL1838349 0.80 RAB9A (0.70) P2RX7LMNACHRM1HTR7HPGD
SCHEMBL2149213 0.80 LMNA (0.68) P2RX7LMNACHRM1CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080009520-A1 BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS ACADIA PHARMACEUTICALS INC. (US) 2008-01-10 US claimed
US-20060205785-A1 Benzimidazolidinone derivatives as muscarinic agents KELLY NICHOLAS M 2006-09-14 US claimed
EP-1432420-B1 BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS ACADIA PHARM INC (US) 2011-07-13 EP disclosed
US-20100216840-A1 BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS ACADIA PHARMACEUTICALS INC. (US) 2010-08-26 US disclosed
US-20080070948-A1 BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS ACADIA PHARMACEUTICALS INC. (US) 2008-03-20 US disclosed
US-20080009520-A1 BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS ACADIA PHARMACEUTICALS INC. (US) 2008-01-10 US disclosed
US-7300928-B2 Benzimidazolidinone derivatives as muscarinic agents ACADIA PHARMACEUTICALS, INC. (US) 2007-11-27 US disclosed
US-7291611-B2 Benzimidazolidinone derivatives as muscarinic agents ACADIA PHARMACEUTICALS INC. (US) 2007-11-06 US disclosed
US-7273857-B2 Benzimidazolidinone derivatives as muscarinic agents ACADIA PHARMACEUTICALS INC. (US) 2007-09-25 US disclosed
US-20060258707-A1 Benzimidazolidinone derivatives as muscarinic agents KELLY NICHOLAS M 2006-11-16 US disclosed
US-20060205785-A1 Benzimidazolidinone derivatives as muscarinic agents KELLY NICHOLAS M 2006-09-14 US disclosed
US-20060199799-A1 Benzimidazolidinone derivatives as muscarinic agents KELLY NICHOLAS M 2006-09-07 US disclosed
US-7087593-B2 Benzimidazolidinone derivatives as muscarinic agents ACADIA PHARMACEUTICALS INC. (US) 2006-08-08 US disclosed
US-20060025402-A1 Benzimidazolidinone derivatives as muscarinic agents KELLY NICHOLAS M 2006-02-02 US disclosed
US-6951849-B2 Benzimidazolidinone derivatives as muscarinic agents ACADIA PHARMACEUTICALS INC. (US) 2005-10-04 US disclosed
US-20040067931-A1 Benzimidazolidinone derivatives as muscarinic agents ACADIA PHARMACEUTICALS INC. 2004-04-08 US disclosed
US-20030100545-A1 Benzimidazolidinone derivatives as muscarinic agents ACADIA PHARMACEUTICALS, INC. 2003-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070948-A1 BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS CHRM4, CHRM1, CHRM2 P2RX7 679/4885LMNA 3610/4885CHRM1 2/4885
US-20030100545-A1 Benzimidazolidinone derivatives as muscarinic agents CHRM4, CHRM5, CHRM1 P2RX7 889/4885LMNA 3578/4885CHRM1 3/4885
US-20060258707-A1 Benzimidazolidinone derivatives as muscarinic agents CHRM4, CHRM1, CHRM2 P2RX7 679/4885LMNA 3610/4885CHRM1 2/4885
US-20100216840-A1 BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS CHRM4, CHRM1, CHRM2 P2RX7 679/4885LMNA 3610/4885CHRM1 2/4885
US-20060025402-A1 Benzimidazolidinone derivatives as muscarinic agents CHRM4, CHRM1, CHRM2 P2RX7 679/4885LMNA 3610/4885CHRM1 2/4885
US-20080009520-A1 BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS CHRM4, CHRM1, CHRM2 P2RX7 679/4885LMNA 3610/4885CHRM1 2/4885
US-20040067931-A1 Benzimidazolidinone derivatives as muscarinic agents CHRM4, CHRM5, CHRM1 P2RX7 889/4885LMNA 3578/4885CHRM1 3/4885
US-20060199799-A1 Benzimidazolidinone derivatives as muscarinic agents CHRM4, CHRM1, CHRM2 P2RX7 679/4885LMNA 3610/4885CHRM1 2/4885
US-20060205785-A1 Benzimidazolidinone derivatives as muscarinic agents CHRM4, CHRM1, CHRM2 P2RX7 679/4885LMNA 3610/4885CHRM1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.